Caffeine Kinetics and CrossFit®-Specific Performance
The Effect of Caffeine and Paraxantine Kinetics on Exercise Performance and Psychophysical State in Athletes After Ingestion of Mono- or Multi-ingredient Caffeine-containing Supplements
Poznan University of Physical Education
25 participants
Jun 29, 2022
INTERVENTIONAL
Conditions
Summary
The study aims at assessing the relation between caffeine (CAF) and paraxanthine (PAX) kinetics after acute ingestion of caffeine (3 mg/kg body mass) in the form or mono- or multi-ingredient preparations and CrossFit®-specific performance or selected indicators of psychophysiological state. Blood indicators of muscle damage/recovery, acid-base balance and electrolytes levels will be evaluated. The impact of genetic variations in the polymorphisms rs5751876 in ADORA2A gene and rs762551 in CYP1A2 on CAF/PAX kinetics will be considered.
Eligibility
Inclusion Criteria5
- written informed consent from all participants before the study,
- a current medical clearance to practice sports,
- training experience any sport discipline ≥ 5 years and training experience in HIFT ≥ 2 years,
- performing ≥3 training units per week,
- participating in CrossFit® competitions at least once a year.
Exclusion Criteria7
- current injury,
- any health-related contraindication,
- declared general feeling of being unwell,
- unwilling to follow the study protocol,
- serious disease or metabolic problems,
- smoking and tobacco use,
- presence of infectious disease in the previous 4 weeks of the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND
CAFMIPS\_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND
CAFMIPS\_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMIPS\_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY.
Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05516212